Company intelligence / Profile preview

Avelos Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Avelos Therapeutics has developed AD1208, a first-in-class MASTL kinase inhibitor that has shown remarkable efficacy in selectively inhibiting cancer cells in both laboratory and animal testing. The company disclosed preclinical research findings for the AVS1001 project at AACR 2024 and is preparing for clinical trials in the second half of 2025.

Therapeutic areas: Oncology
Modalities: Small molecule synthetic drugs
Industry: Biotech

Drug pipeline

5 assets

ad-1208

4 more assets in the full pipeline.

Request access →

Partnerships

Planning to identify collaborative Korean research partners and facilitate global technology transfer in 2025

Beyond the preview

Go deeper on Avelos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avelos Therapeutics.

Explore the full profile